The pleiotropic protein known as transforming growth factor-beta (TGF-) is a member of a superfamily that controls several cellular processes, including growth, development, and differentiation. The Smad proteins, which are the intracellular TGF-beta signaling effectors, are activated by receptors and move into the nucleus where they control transcription. Although this pathway is fundamentally straightforward, cooperation with sequence-specific transcription factors, combinatorial interactions in the heteromeric receptor and Smad complexes, receptor-interacting and Smad-interacting proteins, and other factors enable significant versatility and diversity of TGF-beta family responses. Smad activation and function are further regulated by other signaling pathways.
Additionally, TGF-beta receptors activate Smad-independent pathways that enable Smad-independent TGF-beta responses in addition to regulating Smad signaling. Abnormal TGF- signaling has been linked to a number of illnesses, including cancer, cardiovascular disease, and fibrosis. Consequently, it is acknowledged that the TGF-signaling pathway is a potential drug target.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V67548 | 3,3-Dimethyl-1-butanol (DMB; Neohexanol) | 624-95-3 | 3,3-Dimethyl-1-butanol (DMB) is an orally bioavailable inhibitor of trimethylamine (TMA) and trimethylamine-N-oxide (TMAO). |
|
V67546 | 3,7-DMF | 20950-52-1 | 3,7-DMF is an orally bioavailable inhibitor of TGF-β1-induced HSC activation. |
|
V67554 | Carotuximab (TRC105; DE-122) | 1268714-50-6 | Carotuximab (TRC105) is an IgG1 monoclonal antibody (mAb) that blocks endoglin (CD105) and its downstream Smad signaling pathway. |
|
V67558 | Cirevetmab (ZTS-00521426) | 2473240-98-9 | Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 canine-derived monoclonal antibody (mAb). |
|
V67562 | Dalbergioidin | 30368-42-4 | Dalbergioidin is a well-known anthocyanin that improves doxorubicin-induced renal fibrosis by inhibiting the TGF-β signaling pathway. |
|
V67547 | DT-6 | 2414315-95-8 | DT-6 is a potent inhibitor of TGF-β1. |
|
V67559 | Elezanumab (elezanumab; ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)) | 1791416-49-3 | Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody (mAb) that selectively targets repulsive guide molecule A (RGMa). |
|
V67561 | Hydrochlorothiazid-d2 (HCTZ-d2) | 1219798-89-6 | Hydrochlorothiazid-d2 is the deuterated form of Hydrochlorothiazide. |
|
V67563 | Hydrochlorothiazide-13C6 (HCTZ-13C6) | 1261396-79-5 | Hydrochlorothiazide-13C6 is 13C (carbon 13) labelled Hydrochlorothiazide. |
|
V3250 | LDN-193189 2HCl | 1435934-00-1 | LDN193189 2HCl is the dihydrochloride salt ofLDN193189, which is a highly potent andselective small molecule inhibitor of the BMP (bone morphogenetic protein) signaling pathway. |
|
V67560 | Lerdelimumab (CAT-152) | 285985-06-0 | Lerdelimumab (CAT-152) is a human IgG4 anti-TGF-β2 recombinant monoclonal antibody (mAb). |
|
V67552 | Livmoniplimab (ABBV-151; ARGX-115) | 2412004-88-5 | Livmoniplimab (ABBV-151; ARGX-115) is a potent, humanized anti-LRRC32 (GARP)/TGFβ1 monoclonal antibody (mAb). |
|
V67553 | Luspatercept (ACE-536; luspatercept–aamt) | 1373715-00-4 | Luspatercept (ACE-536) is a recombinantly modified ActRIIB fusion protein that binds to transforming growth factor beta superfamily ligands. |
|
V67566 | Myristoyl tetrapeptide-12 | 959610-24-3 | Myristoyl tetrapeptide-12 directly activates SMAD2 and induces the association of SMAD3 with DNA. |
|
V67565 | Nisevokitug (NIS-793) | 2649854-92-0 | Nisevokitug (NIS-793) is a human IgG2λ antibody targeting TGF-beta (TGFB1/TGFB2). |
|
V2022 | Oxymatrine (Matrine N-oxide) | 16837-52-8 | Oxymatrine (also known as Matrine N-oxide)is a naturally occuring quinolizidine alkaloid isolated from the root of Sophora flavescens, which is used for the treatment of viral hepatitis, cancer, viral myocarditis, gastrointestinal hemorrhage and skin diseases such as colpitis, psoriasis and eczema etc. |
|
V67550 | Ponsegromab (PF 06946860) | 2368950-15-4 | Ponsegromab (PF 06946860) is a potent and specific humanized anti-GDF15 antibody inhibitor (antagonist) with anti-cachexia activity. |
|
V2407 | SIS3 free base | 1009104-85-1 | SIS3 is a potent and selective inhibitor of Smad3 function. |
|
V67551 | SIS3 free base | 521985-36-4 | SIS3 free base is a potent and specific inhibitor of Smad3 phosphorylation. |
|
V2956 | SIS3 HCl | 521984-48-5 | SIS3 HCl is a potent and selective inhibitor of Smad3 which is a receptor-regulated intracellular protein that functions downstream of TGF-β and activin receptors and mediates their signaling, playing a role in cell proliferation, differentiation, apoptosis and formation of extracellular matrix. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
